[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Science Valley Research Institute\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":164},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,5,0,[8,44,77,103,134],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":24,"conditions":25,"keywords":27,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":32,"lastUpdatePostDateStruct":33,"startDateStruct":36,"completionDateStruct":38,"leadSponsor":40,"locationsCount":43},"100593377","brazilian-registry-of-menopausal-health-100593377",false,"NCT07005648","Brazilian Registry of Menopausal Health","Population-based Cross-sectional Observational Study for a Brazilian Registry of Menopausal Women and Associated Factors Related to Clinical Profile, Socioeconomic Aspects, Social Disparities, Access to Healthcare, Quality of Life, and Knowledge About Menopause","Inclusion Criteria:\n\n1. Women aged between 35 and 65 years attending medical consultation at public and private outpatient health services;\n2. Ability to confirm voluntary participation and sign the Informed Consent Form\n\nExclusion Criteria:\n\n1. Inability to respond to the interview for any reason\n2. Suspected or confirmed pregnancy\n3. Lactation\n4. Uncontrolled diabetes\n5. Uncontrolled arterial hypertension\n6. Uncontrolled thyroid disorders\n7. Grade 3 obesity, defined by a BMI equal to or greater than 40.0 kg\u002Fm²\n8. Diagnosis of psychiatric disorders that may compromise participation in the interview\n9. Previous hysterectomy\n10. Previous oophorectomy\n11. Current use of illicit drugs",true,"ALL","35 Years","65 Years",{"count":21,"type":22},1592,"ESTIMATED","OBSERVATIONAL","The Brazilian Registry of Menopausal Health is a national study aimed to better understand the health and quality of life of participants aged 35 to 65 who are in the menopausal transition or postmenopausal phase, including cisgender women and transgender men.\n\nThe study's hypothesis is that significant regional and socioeconomic disparities influence individuals' health, knowledge, and perception of menopause.",[26],"Menopause",[26,28,29,30],"Post Menopause","Menopause Transition","Climateric","RECRUITING","2026-05-18",{"date":34,"type":35},"2026-05-20","ACTUAL",{"date":37,"type":22},"2026-06-30",{"date":39,"type":22},"2026-12-30",{"name":41,"class":42},"Science Valley Research Institute","OTHER",1,{"id":45,"slug":46,"hasResults":11,"nctId":47,"briefTitle":48,"officialTitle":49,"acronym":50,"eligibilityCriteria":51,"healthyVolunteers":11,"sex":17,"minAge":52,"maxAge":53,"enrollmentInfo":54,"targetDuration":4,"studyType":56,"phases":57,"briefSummary":59,"conditions":60,"keywords":62,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":68,"lastUpdatePostDateStruct":69,"startDateStruct":71,"completionDateStruct":73,"leadSponsor":75,"locationsCount":76},"100590984","phase-2-subdermal-implant-bioabsorbable-oxandrolone-pellet-for-rehabilitation-following-anterior-cruciate-ligament-acl-surgical-reconstruction-100590984","NCT06974526","Subdermal Implant-bioabsorbable Oxandrolone Pellet For Rehabilitation Following Anterior Cruciate Ligament (ACL) Surgical Reconstruction","Randomized, Multicenter, Double-blind, Parallel, Placebo-controlled Study to Investigate the Safety and Exploratory Efficacy of the Absorbable Oxandrolone Implant as an Adjuvant Treatment in Rehabilitation Following Anterior Cruciate Ligament (ACL) Surgical Reconstruction (IMOX Study)","IMOX","Inclusion Criteria:\n\nFor male and female participants:\n\n* Ability to confirm voluntary participation and approve the Informed Consent Form;\n* Men and women aged 18 to 60 years (inclusive);\n* Body weight between 50-120 kg for men and 40-90 kg for women;\n* BMI ≤34.9 kg\u002Fm²;\n* Complete ACL rupture visualized by pre-operative magnetic resonance imaging (MRI);\n* Having undergone arthroscopic knee surgery for anterior cruciate ligament (ACL) coverage using an autologous hamstring tendon graft;\n* Presenting with an isolated ACL injury or combined with ligamentous, meniscal, or cartilage lesions visualized by MRI, provided they do not interfere with the rehabilitation protocol.\n* Classification as very active, active, or irregularly active type A according to the International Physical Activity Questionnaire (IPAQ), based on pre-ACL injury physical activity;\n* Adherence to the rehabilitation protocol, having initiated postoperative physiotherapy treatment;\n* Functional range of motion from 0 to 120º and ability to ambulate without crutches;\n* Blood pressure in the seated position in the doctor's office \\\u003C180\u002F95 mmHg;\n* Hematocrit ≤ 50%;\n* ALT less than three times the upper limit of normal;\n* Serum creatinine \\\u003C2 mg\u002FdL;\n* Total bilirubin \\\u003C 3.0 mg\u002FdL;\n* Albumin ≥ 3.5 g\u002FdL;\n\nFor male participants only:\n\n\\- Total PSA ≤ 4.1 ng\u002FmL.\n\nExclusion criteria:\n\nFor female participants only:\n\n* Confirmed or suspected pregnancy;\n* History of childbirth, abortion, or lactation in the last 3 months;\n* Refusal to use permitted contraceptive methods during the study and for 90 days after the end of participation in the study, unless surgically sterile or expressly declaring themselves exempt from the risk of pregnancy due to not engaging in sexual activity or engaging in non-reproductive activity;\n* Clinical signs of hyperandrogenization characterized by: hirsutism defined by a Ferriman-Gallwey score ≥ 8; or alopecia defined by hair loss of at least 50% of the participant's normal hair, which is not obvious from a distance but is only noticeable upon closer inspection; a different haircut may be necessary to cover the hair loss, but does not necessarily require a wig or hairpiece to camouflage it; or Grade 5 acne defined by a predominance of inflammatory acne lesions in the facial area;\n* Polycystic Ovary Syndrome;\n* Known or suspected breast carcinoma;\n\nFor male participants only:\n\n\\- Known or suspected carcinoma of the prostate or male breast;\n\nFor male and female participants:\n\n* Previous serious injury or history of surgery on the lower limbs;\n* Knee injury more than 36 months ago;\n* Unstable longitudinal meniscal tear requiring repair where subsequent postoperative treatment (e.g., immobilization and range of motion limitation) interferes with the rehabilitation protocol;\n* Meniscus suture during ACL reconstruction;\n* Use of patellar, quadriceps, or other hamstring tendon grafts during ACL reconstruction;\n* Known contraindication to hormone use;\n* Any condition that worsens under hormone treatment;\n* Personal history of deep vein thrombosis (DVT);\n* Known coagulopathy;\n* Known chromosomal disorders;\n* Hypersensitivity to anabolic androgenic steroids;\n* Previous treatment failure with Oxandrolone;\n* Use of testosterone (or analogues) and other anabolic androgenic steroids in any pharmaceutical form in the last 3 months;\n* Pituitary tumor;\n* Creatinine levels \\>2 mg\u002FdL or history of chronic kidney disease;\n* Myocardial infarction in the last 6 months;\n* Uncontrolled dyslipidemia;\n* Uncontrolled diabetes;\n* Patients with chronic obstructive pulmonary disease (COPD) unresponsive to bronchodilators;\n* Any contraindication to magnetic resonance imaging (MRI);\n* Claustrophobia;\n* Irregularly active type B or sedentary classification on the International Physical Activity Questionnaire (IPAQ), based on pre-ACL injury physical activity;\n* Athlete engaged in paid physical activity;\n* Known psychiatric diagnosis, including disorder Major or persistent depressive disorder, bipolar disorder, anxiety, social phobia, specific phobias or obsessive-compulsive disorder, psychotic disorder, personality disorder, eating disorder, neurocognitive disorders, and developmental or somatoform disorders (somatization or hypochondria);\n* Presence of voiding disorder;\n* Known diagnosis of fibromyalgia;\n* Current smoking;\n* History of drug abuse;\n* Participation in other clinical trial protocols in the last 30 days;\n* Participant who, in the investigator's opinion, presents other conditions or clinical or laboratory alterations that make them ineligible to participate in the study;\n* The participant came to meet any exclusion criterion verified at the Selection Visit (SV\u002FV1);\n* Presenting postoperative complications such as stiffness and\u002For healing in the knee requiring additional procedures.","18 Years","60 Years",{"count":55,"type":22},96,"INTERVENTIONAL",[58],"PHASE2","Rehabilitation of knee stability and function after anterior cruciate ligament (ACL) reconstruction is slow and costly. The use of anabolic steroids, such as oxandrolone, may aid in the recovery of muscle mass and strength, as well as functional capacity. Oxandrolone, derived from dihydrotestosterone, has high anabolic activity and low androgenic activity (a 13:1 ratio), making it more effective in promoting weight gain with fewer side effects compared to other steroids. Registered by the FDA and previously by ANVISA (National Health Surveillance Agency (Brazil), it is indicated for cases of post-trauma or post-surgery weight loss. The subdermal use of oxandrolone implants is proposed to release the drug directly into the bloodstream, improving efficacy and reducing issues related to oral administration. This study evaluates the safety and tolerability of the absorbable subdermal oxandrolone implant for 24 weeks versus placebo implant in both men and women as an adjuvant treatment during rehabilitation following anterior cruciate ligament (ACL) surgical reconstruction. The serum and pharmacokinetic profile of the oxandrolone implant will be monitored.",[61],"Anterior Cruciate Ligament (ACL) Reconstruction",[63,64,65,66,67],"Anterior cruciate ligament (ACL)","Oxandrolone","Absorbable subdermal implant","Adverse effects","Sarcopenia","2026-02-20",{"date":70,"type":35},"2026-02-24",{"date":72,"type":35},"2025-11-28",{"date":74,"type":22},"2027-04-30",{"name":41,"class":42},6,{"id":78,"slug":79,"hasResults":11,"nctId":80,"briefTitle":81,"officialTitle":82,"acronym":83,"eligibilityCriteria":84,"healthyVolunteers":11,"sex":17,"minAge":4,"maxAge":4,"enrollmentInfo":85,"targetDuration":4,"studyType":56,"phases":87,"briefSummary":89,"conditions":90,"keywords":92,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":96,"lastUpdatePostDateStruct":97,"startDateStruct":99,"completionDateStruct":100,"leadSponsor":102,"locationsCount":43},"100591479","short-and-ultra-short-pulse-nd-yag-1064nm-lasers-omer-smart-and-omer-premium-for-stasis-dermatitis-100591479","NCT06980961","Short and Ultra-short-pulse ND: YAG 1064nm Lasers (Omer Smart and Omer Premium) for Stasis Dermatitis","Short-pulse and Ultra-Short Pulse ND: YAG 1064 Lasers for Stasis Dermatitis Secondary to Chronic Venous Hypertension Treatment: the SUPERSTAR Trial","SUPERSTAR","Inclusion Criteria:\n\n1. Women or men aged 18 to 89 years with stasis dermatitis secondary to venous hypertension\n2. Agreement with the terms of the survey and signing of the informed consent form\n3. Availability to make the necessary appointments for treatment and follow-up\n4. Provide consent to avoid pregnancy during treatment\n5. Have primary venous hypertension already treated (treatment of varicose veins of the lower limbs) by any of the available techniques\n\nExclusion Criteria:\n\n1. Men and women with CEAP 2 to 6, low mobility, no stasis dermatitis.\n2. Peripheral arterial disease.\n3. History of known allergy to the drugs used in this study\n4. Presence of other types of dermatitis in the lower extremities, such as allergic stasis eczema.\n5. Presence of comorbidities (such as diabetes mellitus, heart failure, respiratory failure, hypertension, hypothyroidism, or hyperthyroidism), pregnancy, breastfeeding, pulmonary hypertension, deep vein thrombosis (DVT), family history of DVT, known hypercoagulable states or thrombophilia, asthma, and migraine.\n6. Anyone who does not agree with any of the search terms.\n\n   \\-",{"count":86,"type":22},20,[88],"NA","This study tests two types of lasers (ND YAG 1064 short and ultra-short pulses) to treat hyperchromic skin lesions secondary to venous hypertension (stasis dermatitis)",[91],"Stasis Dermatitis",[93,94,95],"laser","stasis dermatitis","hyperchromic skin lesions","2025-05-12",{"date":98,"type":35},"2025-05-20",{"date":98,"type":22},{"date":101,"type":22},"2026-12-01",{"name":41,"class":42},{"id":104,"slug":105,"hasResults":11,"nctId":106,"briefTitle":107,"officialTitle":108,"acronym":109,"eligibilityCriteria":110,"healthyVolunteers":11,"sex":17,"minAge":4,"maxAge":4,"enrollmentInfo":111,"targetDuration":4,"studyType":56,"phases":113,"briefSummary":115,"conditions":116,"keywords":120,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":126,"lastUpdatePostDateStruct":127,"startDateStruct":129,"completionDateStruct":131,"leadSponsor":133,"locationsCount":43},"100589759","phase-4-pulsed-electromagnetic-field-therapy-or-pneumatic-compression-vte-prophylaxis-100589759","NCT06958588","Pulsed Electromagnetic Field Therapy or Pneumatic Compression VTE Prophylaxis","Pulsed Electromagnetic Field Therapy (PEMF) Compared to Conventional Mechanical Prophylaxis for Venous Thromboembolism Prophylaxis in Patients in the Intensive Care Unit (ICU)","SOPHIE","Inclusion Criteria:\n\n1. Patients \\> 18 years old in ICU\n2. PADUA score\\> 4 (medical patients) and\u002For Caprini score\\> 3 (surgical patients)\n3. Contraindication to pharmacological prophylaxis or indication to combined (pharmacological and mechanical VTE prophylaxis)\n\nExclusion Criteria:\n\n1. Patients \\\u003C 18 years old in ICU\n2. Unable to use mechanical prophylaxis due to trauma, burns, fracture, or problems in inferior members that prevent the use of mechanical prophylaxis\n3. Life expectations less than 24 hours",{"count":112,"type":22},50,[114],"PHASE4","Venous thromboembolism (VTE) is frequent in patients in the intensive care unit (ICU). Pharmacologic prophylaxis is sometimes contraindicated, and mechanical prophylaxis is used. The primary objective of the study is to compare Pulsed Electromagnetic Field Therapy (PEMF) with conventional mechanical prophylaxis for the prevention of VTE in patients in the ICU.",[117,118,119],"Venous Thromboembolism (VTE)","Intensive Care Medicine","Venous Thromboembolism",[121,122,123,124,125],"venous thromboembolism","Mechanical prophylaxis","Pulsed Electromagnetic Field Therapy (PEMF)","ICU","intensive care unit","2025-04-25",{"date":128,"type":35},"2025-05-06",{"date":130,"type":22},"2025-05-25",{"date":132,"type":22},"2026-03-20",{"name":41,"class":42},{"id":135,"slug":136,"hasResults":11,"nctId":137,"briefTitle":138,"officialTitle":139,"acronym":140,"eligibilityCriteria":141,"healthyVolunteers":11,"sex":17,"minAge":4,"maxAge":4,"enrollmentInfo":142,"targetDuration":4,"studyType":56,"phases":144,"briefSummary":145,"conditions":146,"keywords":151,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":156,"lastUpdatePostDateStruct":157,"startDateStruct":159,"completionDateStruct":161,"leadSponsor":163,"locationsCount":43},"100583207","phase-4-vte-incidence-after-rivaroxaban--aspirin-or-sapt-after-lower-limb-revascularization-100583207","NCT06873321","VTE Incidence After Rivaroxaban + Aspirin or SAPT After Lower-limb Revascularization","Incidence of Venous Thromboembolism After Lower Limb Revascularization in Patients Receiving Rivaroxaban 2.5 Mg Bid + Aspirin 100 Mg Versus Single Antiplatelet Treatment - a Randomized Clinical Trial","RESOLUTION","Inclusion Criteria:\n\n1. Be adults of any age and gender.\n2. Have critical limb ischemia with a proposed revascularization treatment (either via ATP or bypass surgery) at the Vascular Surgery Service of HC\u002FEBSERH - UFPE.\n3. Sign the informed consent form (ICF) (Appendix 2).\n\nExclusion Criteria:\n\n1. Experience a symptomatic VTE event during hospitalization, as they will require full anticoagulation rather than prophylactic anticoagulation.\n2. Have any contraindications to Rivaroxaban.\n3. Do not return for the 30-day postoperative follow-up visit.",{"count":143,"type":22},100,[114],"Venous thromboembolism (VTE) has a high prevalence in patients with multiple comorbidities undergoing complex surgical procedures. Sometimes, extended prophylaxis for VTE with KLMWH or direct oral anticoagulants (DOACs) is necessary. Currently, there is no consensus in the literature regarding the use of DOACs for extended VTE prophylaxis in patients undergoing lower limb revascularization (LLR). Objective: To evaluate the use of DOACs (already approved to reduce MACE and MALE) in VTE prophylaxis in patients undergoing LLR.",[147,148,149,150],"Peripheral Arterial Disease","Venous Thormboembolism","Cardiovascular Diseases","Vascular Surgery Patient with PAD \u002F Carotid Stenosis",[147,152,153,121,154,155],"chronic limb-threatening ischemia","Deep Vein Thrombosis","Factor Xa Inhibitors","rivaroxaban","2025-03-06",{"date":158,"type":35},"2025-03-12",{"date":160,"type":35},"2024-02-24",{"date":162,"type":22},"2025-07-30",{"name":41,"class":42},""]